Clinical development

Programs built on WEE1 biology

A focused, late-stage clinical portfolio led by our biomarker-driven, oral WEE1 inhibitor across patient populations with significant unmet need.

Explore trial participation Pipeline overview

By indication

Explore each program

Phase 3 · ASPENOVA

Cyclin E1-positive platinum-resistant ovarian cancer

Evaluating the first oral, non-chemotherapy, biomarker-driven approach for this patient population — transforming decades of WEE1 research into a novel targeted option.

Find a trial Speak with our team
  • DesignRegistration-intent, global
  • Patient markerCyclin E1 positive
  • ComparatorStandard-of-care
  • DosingOral, once daily
  • StatusEnrolling

Development journey

How our programs move forward

  1. 01

    Discovery

    Deep mechanistic biology of cell-cycle control pinpoints novel, druggable targets.

  2. 02

    Preclinical

    Compound selection, biomarker validation and registration-ready study design.

  3. 03

    Clinical development

    Global, biomarker-driven trials advancing from first-in-human to registration.

  4. 04

    Patient impact

    An oral, convenient therapy designed to unburden patients and their families.

For patients Thinking about a clinical trial? Find trial sites near you and learn what to expect at every step.

Patient participation

Trials designed with patients in mind

Participation is a personal decision. Our team is here to help you understand what a trial involves — from screening to the final study visit.

Always speak with your care team first. If a Zentia trial could be right for you, we'll connect you with the study team to confirm eligibility and answer every question.

  • Companion diagnostic screening at participating sites
  • Oral therapy — no infusion visits required
  • Support resources for patients and caregivers
Explore clinical trials Read the FAQ